APOE and Alzheimer disease: APOE4 zygosity also impacts neuroimaging and plasma biomarkers of AD in the absence of dementia, with APOE3/4 carriers generally aligning more closely with APOE3/3 than APOE4/4 carriers (Tato-Fernandez et al., 2024).